FDA Expresses Displeasure with Consumer Products Containing Trendy Cannabis Ingredient Delta-8 THC
On May 4, 2022, the U. S. Food and Drug Administration (FDA) for the first time issued warning letters related to products containing delta-8 tetrahydrocannabinol (delta-8 THC). FDA has previously sent warning letters to other companies illegally selling unapproved and misbranded cannabidiol (CBD) products that claimed to treat illness in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act), as we have discussed in prior posts (one example here). In a separate recent slew of CBD-related actions, FDA issued warning letters jointly with the Federal Trade Commission (FTC) to seven companies for selling CBD products with claims that they will treat or prevent COVID-19. (FDA has not approved any CBD-containing products other than one prescription human drug product to treat rare, severe forms of epilepsy. ) However, the recent delta-8 THC letters are focused on FD&C Act violations and only signed by FDA officials, notwithstanding that FTC advertising issues likely exist for those products too, suggesting that the agency may have wanted to send a clear message about the risk to the public health and the FD&C Act problems with such products.Hit on delta 8 thc texas to explore more about our services and sites. Hope you ll like our more services.
Delta-8 THC is a cannabinoid occurring naturally in the Cannabis sativa plant, of which marijuana and hemp are two varieties. Delta-8 THC products have proliferated since the passage of the Agriculture Improvement Act of 2018, but FDA has remained relatively hands-off when it comes to enforcement related to these products. The warning letters issued on May 4 indicate that advertising delta-8 THC products as capable of treating or preventing sickness or disease will elicit action from the agency.